Oncotype DX AR-V7 NUCLEUS DETECT

Interpreting AR-V7 Nucleus Detect Test results

Accurately identify patients resistant to targeted therapies

For patients with metastatic castration-resistant prostate cancer (mCRPC), the Oncotype DX AR-V7 Nucleus Detect Test lets you quickly and confidently determine the likely benefit of androgen receptor (AR)-targeted therapies, like Abiraterone (Zytiga®), Enzalutamide (Xtandi™), and Apalutamide (Erleada™).

  • Accurately identify patients who are unlikely to benefit from AR-targeted therapies.1-3
  • Predict whether taxanes or AR-targeted therapies may offer improved overall survival.1,2
  • Results are easy to interpret (positive or negative).

Interactive report guide

Quickly and easily understand how to interpret the AR-V7 Nucleus Detect Test report.


See sample reports

For patients with:

Getting your results

Most Oncotype DX AR-V7 Nucleus Detect Test results are available within two weeks of the date we receive your patient's sample at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.

START REPORT GUIDE
START REPORT GUIDE
REFERENCES
  1. Scher, HI, et al. JAMA Oncol. 2016.
  2. Scher, HI, et al. JAMA Oncol. 2018.
  3. Armstrong, AJ, et al. JAMA Oncol. 2018.

XTANDI is a trademark of Astellas Pharma Inc. Zytiga is a trademark of Janssen Biotech, Inc. Erleada is a trademark of Janssen Biotech, Inc.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.